Evasc Neurovascular Announces First Neuro Product Approved in French Forfait Innovation Program
23.2.2021 09:29:00 EET | Business Wire | Press release
Evasc Neurovascular is proud to announce its successful application to France’s Ministry of Health (Haute Autorité de la Santé, HAS) Forfait Innovation (FI) program for the eCLIPs™ device, published in its official journal December 23, 2020 - https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042722732.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005015/en/
The eCLIPs device is the first neuro device that has gained Forfait Innovation approval and funding (Graphic: Business Wire)
The Forfait Innovation program grants clinical trial funding to evaluate CE marked devices that are deemed to be truly innovative (not simply incremental developments) and offer significant clinical benefit, filling an unmet medical need. The eCLIPs device is the first neuro device that has gained FI approval and funding. The funded amount of €2.76 million covers hospital costs of a 119-patient trial against optimal performance criteria (OPC).
Dr. Donald Ricci, CEO of Evasc Neurovascular, comments, “We are pleased to have confirmation by an influential and independent third party, the French Ministry of Health, that eCLIPs represents an innovation in the treatment of intracranial bifurcation aneurysms, a consistent message in our presentations, publications and discussions with neuro-interventionalists over the past few years.”
About the eCLIPs Aneurysm Treatment System
eCLIPs is a non-tubular endovascular device currently targeted for use in challenging wide-neck bifurcations, using technology designed to treat 95% of cerebral aneurysm cases. The unique eCLIPs design provides not only coil retention, but also flow diversion at the neck. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac while leaving side branches unencumbered and providing a platform for endothelial growth across the bifurcation neck.
About Evasc Neurovascular
Evasc Neurovascular is a privately-held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc Neurovascluar is headquartered in Vancouver, Canada.
Visit Evasc Neurovascular at www.evasc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005015/en/
Contact information
Scott Wilson
+1 (604) 742-3811
wilson@evasc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
Andersen Consulting Broadens Data and Analytics Capabilities with Insight Consulting18.2.2026 16:30:00 EET | Press release
Andersen Consulting adds depth to its platform through a Collaboration Agreement with Insight Consulting, a leading data and digital strategy consultancy with a presence in South Africa, Mozambique, and the UK. Insight Consulting provides end-to-end services across the digital value network, including digital strategy, digital fluency, enterprise AI, custom software development, data integration, analytics, and planning and forecasting. Its multidisciplinary teams bring expertise in people, technology, and process, ensuring that effective change management encompasses all three of these elements. The firm works across industries such as retail, logistics, hospitality, finance, manufacturing, travel, agriculture, automotive, and healthcare. “Collaborating with Andersen Consulting gives us access to a wider global footprint and advanced methodologies, while also allowing us to contribute our regional knowledge and expertise in data and analytics,” said Sean Taylor, director of Insight Co
Cubic Corporation Optimizes SAP Support with Rimini Street to Accelerate Modernization18.2.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Cubic Corporation, innovation technology provider for the defense and transportation industry, has partnered with Rimini Street to support its strategy to modernize while maintaining SAP ECC as a stable core and to explore AI and automation initiatives across its broader application landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218871248/en/ Cubic Corporation Optimizes SAP Support with Rimini Street to Accelerate Modernization The strategy to forgo an expensive upgrade to S/4HANA and instead support and optimize its systems with Rimini Street has enabled Cubic to free up significant resources of people, time and money to reinvest in feature-rich applications, leading-edge AI technologies and efficiency initiatives, including impr
Safe Software Launches FME Flow Availability in AWS Marketplace18.2.2026 16:00:00 EET | Press release
Today, Safe Software, the creator of FME, the All-Data, Any-AI enterprise integration platform with true support for spatial data, announced that FME Flow is now available in AWS Marketplace, which helps organizations easily discover, try, test, buy, deploy and manage thousands of software solutions, including pre-built AI agents and ready-to-integrate tools, all in one convenient destination. Amazon Web Services (AWS) customers can now purchase FME Flow directly within AWS Marketplace, simplifying billing and procurement and providing faster access to Safe Software’s enterprise-grade data automation capabilities. Safe Software’s FME connects all data across data velocities, locations, and types. FME Flow delivers many data workflow services to enterprise users. Availability in AWS Marketplace allows organizations to streamline the purchase and management of FME Flow directly within their AWS Marketplace account. “As the data landscape becomes increasingly complex and distributed, flex
FDA Approval Granted for Commercial Manufacturing at Rezon Bio's Warsaw-Duchnice Facility18.2.2026 15:01:00 EET | Press release
Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio’s global manufacturing network and reflects the company’s focus on building robust, compliant, and reliable capabilities to support biologic therapies for patients worldwide. The FDA approval of the Warsaw-Duchnice facility follows a comprehensive review process and reflects the maturity of the site’s quality systems, technical capabilities, and operational readiness for commercial supply to the US market. This approval is coming subsequent to previous EMA GMP certification and approval for commercial supply to European markets. Such approval further strengthens Rezon Bio’s ability to support clients in needs to supply EU and US territories and enhances its position as a reliable partner within the Contract Development and Manufa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom